#United States #New York #Securities Fraud #Pomerantz LLP #Abacus Global Management

Pomerantz Law Firm Investigates Abacus Global Management

In a significant development for investors of Abacus Global Management, Inc. (NASDAQ: ABL), the Pomerantz Law Firm has announced that it is conducting an investigation into potential securities fraud and other unlawful business practices involving the company. This inquiry follows allegations raised in a report published by Morpheus Research, which casts a skeptical light on Abacus's financial practices and operational methodologies.

Background on Abacus Global Management

Founded with a vision to innovate in the financial services sector, Abacus Global Management has grown into a notable firm in the SPAC (Special Purpose Acquisition Company) landscape. However, recent events are threatening to overshadow its reputation and operational integrity. With a peak market valuation of $794 million, the firm is now under scrutiny following a research publication that claims it has been misrepresenting its financial health.

On June 4, 2025, Morpheus Research released a report titled "Abacus Global Management: This $794 Million SPAC Is Yet Another Life Settlements Accounting Scheme Manufacturing Fake Revenue By Systematically Underestimating When People Will Die." The authors of this report assert that the company altered its portfolio valuation methodology to artificially inflate profits, painting a misleading picture of its financial condition.

Allegations of Fraud and Misconduct

One of the most shocking allegations claims that Abacus employs questionable methods for estimating life expectancies. This is critical information as the company deals primarily in life settlement investments, which depend heavily on accurate mortality predictions. Furthermore, the report brought to light historical concerns regarding the company's co-founders, suggesting a pattern of misconduct that may have persisted over the years.

The impact of these revelations on Abacus was swift. Following the Morpheus report’s release, the stock price plummeted by $1.64 per share, or 21.47%, closing at $6.00 on June 5, 2025. This drastic decline reflects the market's immediate reaction to the unearthing of potential corporate malpractice, triggering concern among investors.

Pomerantz's Role and Invitation to Investors

The Pomerantz Law Firm, renowned for its commitment to fighting corporate misconduct, has opened the investigation to assess how these allegations may have affected shareholders. The firm is encouraging anyone who has invested in Abacus to reach out for more information about potential legal remedies. Investors can contact Danielle Peyton via email or phone for assistance.

Pomerantz LLP, with locations spanning across New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is a well-respected name in class action law. Since its founding, the firm has built a legacy of protecting the rights of individuals harmed by corporate misdeeds and has a history of securing substantial settlements on behalf of its clients.

As this situation unfolds, the implications for Abacus and its investors remain uncertain. However, the investigation by Pomerantz signals a critical step in potentially holding accountable those responsible for any wrongdoing within the company. Investors must stay vigilant and informed about the developments in this case as they navigate the implications.

Conclusion

The ongoing dialogue around Abacus Global Management emphasizes the importance of transparency and ethical practices within the financial sector. As Pomerantz continues to gather information, the hope is that justice will be served for those who may have fallen victim to misleading business practices. Investors are encouraged to remain engaged and proactive in seeking information regarding their investments and safeguarding their rights amidst evolving circumstances.